Media headlines about biOasis Technologies (CVE:BTI) have been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. biOasis Technologies earned a news sentiment score of -1.55 on their scale. InfoTrie also gave news stories about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock’s share price in the near future.
Shares of biOasis Technologies stock traded down C$0.01 during trading on Thursday, reaching C$0.32. 43,500 shares of the company’s stock were exchanged, compared to its average volume of 49,027. biOasis Technologies has a 1-year low of C$0.26 and a 1-year high of C$1.02.
WARNING: This piece was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/09/bioasis-technologies-bti-given-daily-coverage-optimism-score-of-1-55.html.
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
Featured Article: Discount Rate
Receive News & Ratings for biOasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biOasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.